Erratum: Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. November (Leukemia and Lymphoma (2013) 54:11 (2506-2516) DOI: 10.3109/10428194.2013.776681);Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2506-2516

  Zhang, Wei ^a   Chen, Bao An ^a   Jin, Jun Fei ^a   He, You Ji ^a   Niu, Yi Qi ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

5 bromotetrandrine; C Jun NH2 terminal kinase; Hypoxia; Multidrug resistance

Indexed keywords

5 BROMOTETRANDRINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; CASPASE 3; DAUNORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL HYPOXIA; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; HUMAN; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLISOQUINOLINES; CASPASE 3; CELL HYPOXIA; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; K562 CELLS; LEUKEMIA; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84885574573     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2016.1158967     Document Type: Erratum

References (39)

1. Chen H, Bi W, Gao B, et al. A novel podophyllotoxin derivative (YB1EPN) induces apoptosis and down-regulates express ofP-glycoprotein in multidrug resistance cell line KBV200. Eur J Pharmacol. 2010;627:69-74.
2. Sipos G, Kuchler K. Fungal AlP-binding cassette (ABC) transporters in drug resistance and detoxification. Curr Drug largets.2006;7: 471-48 1.
3. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006;580:2903-2909.
4. Raguz 5, Tamburo De Bella M, et al. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res 2004;10:2776-2783.
5. Zhou J, Liu M, Aneja R, et al. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006;66:445-452.
6. Liu M, Li DW, Aneja R, et al. P02-dependent diftèrential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem 2007;282:17581-17586.
7. Katrina M. Comerford, Boin P. Cummins, Cormac EL Taylor, et al. c-Jun NH2-terminal kinase activation contributes to hypoxia-1nducible factor ict-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004; 64:9057-9061.
8. Comerford KM, Wallace TJ, Karhausen J, et al. Hypoxia-1nducible factor-I-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394.
9. Wartenberg M, Ling FC, Muschen M, et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-1nducible factor i(HIF-1) and reactive oxygen species. FASEB J 2003;i7:503-505.
10. Osborn Ml, Chambers TC. Role ofthe stress-activated/c-Jun NH2-terminal kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 1996;27i:30950-30955.
11. Juneja J, Casey PJ. Gi2 signaling through c-Jun NH2-terminal kinase promotes breast cancer cell invasion. PbS One. 2011;6:I-8.
12. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO 1996;i5:2760-2770.
13. Frolova 0, Samudio I, Benito JM, et al. Regulation of HIF-1ct signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther 2012;i3:858-870.
14. Ledoux 5, Yang R, Friedlander G, et al. Glucose depletion enhances P-glycoprotein expression in hepatoma cells: Role of endoplasmic reticulum stress response. Cancer Res 2003;63:7284-7290.
15. Comerford KM, Cummins EP, Taylor CE c-Jun NH2-terminal kinase activation contributes to hypoxia inducible factor ia-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057-906i.
16. Jin J, Wang FP, Wei HL, et al. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-Brlet. Cancer Chemother Pharmacol 2005;55,i79-188.
17. Wang FP, Wang L, Yang JS, et al. Reversal of P-glycoproteindependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 2005;28:I979-1982.
18. Zheng L, Qing YP, Xu N, et al. Pharmacokinetics and safety of bromotetrandrine (Brlet, Wi98) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther 2010;35:113-119.
19. Liu XD, Sun H, Liu GEL 5-Bromotetrandrine enhances the sensitivity of doxorubicin-Induced apoptosis in intrinsic resistant human hepatic cancer Be17402 cells. Cancer Lett 2010;292:24-3i.
20. Li G, Xiang Y, Sabapathy K, et al. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 2004;279:1123-113i.
21. Jin J, Mullen TD, Hou Q, et al. AMPK inhibitor compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res 2009;50:2389-2397.
22. Juneja J, Cushman I, Casey PJ. Gi2 signaling through c-Jun NH2-terminal kinase promotes breast cancer cell invasion. PLoS One 2011;6:E26085.
23. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Tnt J Cancer 2002;iO:584-592.
24. lidefelt U, Liliemark J, Gruber A, et al. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000;i8:I837-1844.
25. Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res 2003;63:4527-4532.
26. Cheng L Wu WW, Chen BA, et al. Effect of magnetic nanoparticles of Fe304 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Tnt J Nanomed 2009:4:209-216.
27. Alfranca A, Gutierrez MD, Vara A, et al. c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-Induced gene transcription. Mob Cell Biol 2002;22:I2-22.
28. PoulakiV, Mitsiades CS, McMullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor 1 in thyroid carcinomas. J Clin Endocrinol Metab 2003;88:5392-5398.
29. Kimbro KS, Simons JW. Hypoxia-1nducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006;i3:739-749.
30. Sui H, Wang Y, Liu X, et al. COX-2 contributes to P-glycoproteinmediated multidrug resistance via phosphorylation of c-Jun at 5er63/73 in colorectal cancer. Carcinogenesis 2011;32:667-675.
31. Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: Redundancy and specificity. Oncogene 2001;20:2378-2389.
32. Shaulian E, Karin M. APi in cell proliferation and survival. Oncogene 2001;20:2390-2400.
33. Lock-Andersen J, Horn J, Sjostrand H. [Prognosis after sentinel node biopsy in malignant melanoma]. Ugeskrift Laeger 2006 168 2457-2462.
34. Eberle J, Kurbanov BM, Hossini AM, et al. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat 2007;iO:2i8-234.
35. Miao ZH, Tang I, Zhang YX, et al. Cytotoxicity and apoptosis induction by the anti-topoisomerase 11 agent, salvicine, associated with downregulating P-glycoprotein expression in multidrug-resistant cells. Tnt J Cancer 2003;106:108-115.
36. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-2614.
37. Fan M, Goodwin M, Vu T, et al. Vinblastine-Induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 2000;275:29980-29985.
38. Smyth MJ, Krasovskis E, Sutton VR, et al. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998;95:7024-7029.
39. Ruefli AA, Smyth MJ, Johnstone RW. HMBA induces activation of a caspase-1ndependent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000;95: 2378-2385.